Division of Urology, Duke Cancer Institute, Durham, NC; Division of Urology, Maimonides Medical Center, Brooklyn, NY.
Division of Urology, Duke Cancer Institute, Durham, NC.
Urol Oncol. 2022 May;40(5):199.e9-199.e14. doi: 10.1016/j.urolonc.2022.03.002. Epub 2022 Apr 2.
Cryoablation offers a treatment option for small renal masses ideally suited ≤3 cm. In well-selected candidates, it is associated with less perioperative morbidity compared to more invasive options, such as partial or radical nephrectomy. However, little is known regarding device-related complications associated with the procedure. We provide an analysis of reports on renal cryoablation from the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database.
Reports on renal cryoablation submitted to the MAUDE database from 2015 through 6/2021 were analyzed. Cases not pertaining to renal cryoablation were excluded (n = 33). Reports were examined to identify patient morbidity related to a potential device malfunction, as well as manufacturer assessment. Complications were graded based on an established MAUDE complication-reporting stratification. Fisher's Exact test was utilized to analyze for associations between device-related adverse events and severity of post-treatment sequelae.
Two hundred and thirty-nine unique cases were identified. Adverse events were related to issues with the needles or system (212 cases), technical error (12 cases), or complication related to patient or tumor complexity (14 cases). There were 187 (78.6%) minor complications (MAUDE 1-2) and 52 (21.4%) major complications (MAUDE 3-4). The manufacturer performed formal device review in 164 (68.6%) cases, accepting responsibility for malfunction in 41. Notable MAUDE 3 complications included 29 (12.1%) cases aborted due to instrument/system malfunction and 14 (5.9%) cases of hemorrhage requiring a subsequent procedure. All 3 reported patient deaths (MAUDE 4) appeared to be a consequence of poor baseline health. On statistical analysis, major complications were seen in a significantly higher proportion of non-device related adverse events compared to device related events (85.2% vs. 13.7%, P < .001).
While renal cryoablation is associated with low overall perioperative morbidity, there is a diverse set of device-related and procedural complications reported in recent years. Device-related adverse events were often associated with minor complications, and major complications were often seen in higher risk patients with comorbidities, more complex tumors, and after technical error. These findings highlight the need for standardized reporting of complications, optimized patient selection and counseling to ensure the best outcomes.
冷冻消融术为直径理想 ≤3 厘米的小肾肿瘤提供了一种治疗选择。与部分或根治性肾切除术等更具侵入性的选择相比,冷冻消融术在选择合适的患者时与围手术期发病率较低相关。然而,对于与该手术相关的器械相关并发症知之甚少。我们提供了对食品和药物管理局制造商和用户设施设备经验(MAUDE)数据库中冷冻消融术报告的分析。
分析了 2015 年至 2021 年 6 月期间向 MAUDE 数据库提交的与肾脏冷冻消融术相关的报告。排除了与肾脏冷冻消融术无关的病例(n=33)。检查报告以确定与潜在器械故障相关的患者发病率,以及制造商的评估。根据既定的 MAUDE 并发症报告分层,对并发症进行分级。利用 Fisher 精确检验分析器械相关不良事件与治疗后后遗症严重程度之间的关系。
确定了 239 例独特病例。不良事件与针或系统问题(212 例)、技术错误(12 例)或与患者或肿瘤复杂性相关的并发症(14 例)有关。有 187 例(78.6%)为轻度并发症(MAUDE 1-2 级),52 例(21.4%)为重度并发症(MAUDE 3-4 级)。制造商对 164 例(68.6%)病例进行了正式的设备审查,其中 41 例对故障负责。值得注意的 MAUDE 3 级并发症包括 29 例(12.1%)因仪器/系统故障而中止的病例和 14 例(5.9%)需要进一步手术的出血病例。所有 3 例报告的患者死亡(MAUDE 4 级)似乎都是由于基线健康状况不佳所致。在统计学分析中,与器械相关的不良事件相比,非器械相关不良事件中重度并发症的比例明显更高(85.2%比 13.7%,P<.001)。
虽然冷冻消融术与总体围手术期发病率较低相关,但近年来报告了一系列不同的与器械相关和手术相关的并发症。与器械相关的不良事件通常与轻度并发症相关,而重度并发症通常见于风险更高的合并症、更复杂的肿瘤和技术错误的患者。这些发现强调需要标准化报告并发症,优化患者选择和咨询,以确保最佳结果。